Difference between revisions of "Selumetinib (Koselugo)"

Revision as of 21:19, 15 December 2015

Inhibits the enzyme MAPK kinase (MEK), specifically the MEK1 and MEK2 subtypes of the enzyme.

Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb;14(2):134-40. Epub 2012 Dec 21. link to original article PubMed

@@ Line 3: / Line 3: @@
 ==Preliminary data==
-''While this drug has been mentioned as "promising" numerous times, there are no phase II or phase III studies that have been published thus far with a clear beneficial effect.''
+===[[Ovarian cancer]]===
+# Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb;14(2):134-40. Epub 2012 Dec 21. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627419/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/23261356 PubMed]
 [[Category:Drug index]]
@@ Line 11: / Line 13: @@
 [[Category:Kinase inhibitors]]
 [[Category:MEK inhibitors]]
+[[Category:Ovarian cancer medications]]
 [[Category:Investigational]]